Co-Diagnostics Statistics

Total Valuation

Co-Diagnostics has a market cap or net worth of $8.85 million. The enterprise value is -$10.70 million.

Market Cap	8.85M
Enterprise Value	-10.70M

Important Dates

The next estimated earnings date is Thursday, August 7, 2025, after market close.

Earnings Date	Aug 7, 2025
Ex-Dividend Date	n/a

Share Statistics

Co-Diagnostics has 33.71 million shares outstanding. The number of shares has increased by 4.93% in one year.

Current Share Class	33.71M
Shares Outstanding	33.71M
Shares Change (YoY)	+4.93%
Shares Change (QoQ)	+3.80%
Owned by Insiders (%)	7.81%
Owned by Institutions (%)	17.51%
Float	31.08M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	2.32
Forward PS	n/a
PB Ratio	0.18
P/TBV Ratio	0.41
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 4.43, with a Debt / Equity ratio of 0.04.

Current Ratio	4.43
Quick Ratio	4.02
Debt / Equity	0.04
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -56.80% and return on invested capital (ROIC) is -36.62%.

Return on Equity (ROE)	-56.80%
Return on Assets (ROA)	-33.82%
Return on Invested Capital (ROIC)	-36.62%
Return on Capital Employed (ROCE)	-77.10%
Revenue Per Employee	$26,497
Profits Per Employee	-$271,668
Employee Count	132
Asset Turnover	0.05
Inventory Turnover	0.60

Taxes

In the past 12 months, Co-Diagnostics has paid $46,608 in taxes.

Income Tax	46,608
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -80.26% in the last 52 weeks. The beta is 0.58, so Co-Diagnostics's price volatility has been lower than the market average.

Beta (5Y)	0.58
52-Week Price Change	-80.26%
50-Day Moving Average	0.31
200-Day Moving Average	0.72
Relative Strength Index (RSI)	41.95
Average Volume (20 Days)	491,371

Short Selling Information

The latest short interest is 282,095, so 0.84% of the outstanding shares have been sold short.

Short Interest	282,095
Short Previous Month	391,378
Short % of Shares Out	0.84%
Short % of Float	0.91%
Short Ratio (days to cover)	0.41

Income Statement

In the last 12 months, Co-Diagnostics had revenue of $3.50 million and -$35.86 million in losses. Loss per share was -$1.17.

Revenue	3.50M
Gross Profit	2.71M
Operating Income	-38.37M
Pretax Income	-35.81M
Net Income	-35.86M
EBITDA	-37.05M
EBIT	-38.37M
Loss Per Share	-$1.17

Full Income Statement

Balance Sheet

The company has $21.48 million in cash and $1.93 million in debt, giving a net cash position of $19.55 million or $0.58 per share.

Cash & Cash Equivalents	21.48M
Total Debt	1.93M
Net Cash	19.55M
Net Cash Per Share	$0.58
Equity (Book Value)	47.92M
Book Value Per Share	1.43
Working Capital	18.45M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$29.41 million and capital expenditures -$437,972, giving a free cash flow of -$29.85 million.

Operating Cash Flow	-29.41M
Capital Expenditures	-437,972
Free Cash Flow	-29.85M
FCF Per Share	-$0.89

Full Cash Flow Statement

Margins

Gross Margin	77.52%
Operating Margin	-1,097.15%
Pretax Margin	-1,023.95%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Co-Diagnostics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-4.93%
Shareholder Yield	-4.93%
Earnings Yield	-405.22%
FCF Yield	-337.28%

Analyst Forecast

The average price target for Co-Diagnostics is $5.50, which is 1,995.24% higher than the current price. The consensus rating is "Buy".

Price Target	$5.50
Price Target Difference	1,995.24%
Analyst Consensus	Buy
Analyst Count	2
Revenue Growth Forecast (5Y)	175.27%
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Co-Diagnostics has an Altman Z-Score of -0.09 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-0.09
Piotroski F-Score	2